resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence". Although the military experience with whole blood transfusion practice has been successful, there have been complications as vein thrombosis, renal failure, respiratory distress and one case of transfusion-associated graft-versus-host disease. It has been speculated that these complications to some part may be related to the white cells in the whole blood units.
Correspondingly, there is a refreshed interest in leukocyte-reduced whole blood -produced by a method sparing the platelets. Leukocyte reduced whole blood is defined as 450-500 mL whole blood in 63 mL CPD-A, filtered to remove leukocytes to a residual content less than 10 6 . Many filters have been developed, both for whole blood, red cell-and platelet concentrates but in the late 1990 many blood bank leaders were interested in filters sparing platelets as sufficient platelet function is essential in transfusion therapy of patients with massive bleedings. Thus for purpose of this paper, leukocyte reduced whole blood is defined as leukocyte reduction with platelet sparing filtration. As literature is sparse concerning clinical experience with leukodepleted whole blood containing platelets, these considerations are partly based on knowledge established from clinical use of conventional blood components.
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Febrile non-hemolytic transfusion reaction
Febrile non-hemolytic transfusion reaction is defined as a type of transfusion reaction, which is associated with fever but not directly with hemolysis. Temperature elevation should be at least 1°C with a serious reaction defined as elevation above 2°C. Leukocyte reduction of whole blood by filtration is performed shortly after donation, whereas leukocyte reduction of cell concentrates is done up to 24 hours after donation. There is no reason to think that leukocyte-reduced whole blood should give more febrile reactions since these reactions are linked to cytokines. A recent publication presenting data from a study with a platelet-removing whole blood filter supports this although one could argue that the platelet-derived cytokines could be the most important contributor. (27) Allergic reactions
The symptoms of an allergic transfusion reaction are usually mild and include urticarial, skin redness and itching. Severe systemic reactions (anaphylaxis) may occur, including lifethreatening respiratory distress and hypotension, dyspnea, nausea and vomiting. As the symptoms are related to the donor plasma, the number of donor exposure maybe significantly decreased by use of whole blood compared to component therapy. On the other hand, use of pooled plasma instead of single-donor plasma seems to reduce allergic symptoms likely secondary to dilution effect as well as the addition of neutralizing antibodies. According to hemovigilance reports from many countries, "wrong" blood is the major cause for these severe transfusion reactions. (28) The risks will be substantially reduced if only "low titre" O donors are used for whole blood transfusions and group O red cell and platelet donors and group AB plasma donors for reconstituted whole blood. (29) Although there is no officially set standard for a "low titer" there is a general acceptance of an A-and B-antibody titer below 1/100 for IgM and 1/400 for IgG type antibodies as an acceptable low level.
Transfusion related lung injury (TRALI)
In many western countries, TRALI is now the most common transfusion-related cause of death.
TRALI can be defined as acute lung injury (ALI) that occurs during transfusion or within six hours of transfusion, if the reaction is not explained by other ALI risk factors. The aetiology of TRALI is related to donor/blood unit factors as HLA-antibodies and other antibodies in the patients and biologic response modifiers in the blood bags. Antibodies in the patient may also be involved, and yet to be described factors in the patient's illness may predispose to the condition.
For both whole blood and reconstituted whole blood the use of only male, not-transfused donors (whole blood, platelets and plasma) seems to reduce the risk. (30) Transfusion-associated graft versus host disease (TA-GvHD) This is a rare transfusion reaction, but the mortality is around 90%. Immune competent donor lymphocytes engraft in the recipient and cause rejection of the host, as the host is unable to mount a response due to HLA one-way compatibility or immunosuppression. The patient is usually dying of intractable diarrhea. This reaction may be prevented by irradiation or x-ray treatment of the units. Since this treatment is unavailable in remote locations, there is a risk related to "buddy" transfusion and in other circumstances where whole blood or cellular components are transfused without treatment. This is documented from a case history during US military operations. (31) The risk in susceptible patients is estimated at 0.1 -1%.
Transfusion-transmitted infection (TTI)
The risk of infecting patients through transfusion has always been a major concern in transfusion practice. Although donor information and selection, donor questionnaire, extensive testing and products pathogen reduction technologies are implemented, causing the residual risk to be in the 10 -5 , this is still the major concern among the public and also among many health professionals.
Despite the low risk, documentation from recent military experience demonstrates that some patients are infected through transfusion. It is obvious that in austere environments, blood donor selection cannot be performed as in a civilian blood bank. Currently, there are limited number rapid testing methods for infectious markers compared to the sophisticated test panels that may be used in a civilian blood center.
Whole Blood -Is ABO type-specific necessary?
The ABO-blood group substances consist of carbohydrate chains and are shared with bacteria and plant seeds (32). As the antigenic substances are adsorbed from the intestinal bacteria all individuals from 3 months of age carry preformed antibodies of IgM type against the other A/B blood groups in their plasma. These antibodies are complement activating and strongly hemolysing. The ABO blood group substances also exists as free molecules in the plasma and forms soluble ABO-immuncomplexes, thereby lowering the risk for intravascular hemolysis. The adverse effect in the recipient from the transfusion of ABO-incompatible plasma can be separated into immediate, delayed (within 1h-4 days) and late effects (Table II) transfusions and that this is a relatively safe procedure particularly if the donor is "low titer".
Currently the American Association of Blood Banks (AABB) standard 5.14.1 states "Recipients shall receive ABO-specific Whole Blood or ABO group compatible Red Blood Cell components". (36) The AABB also states that if plasma incompatible blood is transfused that the hospital must have a plan to monitor and mitigate possible consequences. Based on the AABB standard as well as the novel concept of using low titer O-type whole blood for hemorrhagic shock in the civilian hospitals, the authors recommend a prospective randomized trial be performed to evaluate the risks and benefits.
Storage of Whole Blood
As fresh whole blood contains all the constituents of the blood -except the white cells if removed by filtration, is considered to be an excellent product. This is indicated in vivo by reports from both military and civilian use, and in vitro from quality control records and publications related to use of platelet sparing whole blood filters. (37) The major challenges are therefore related to storage time and temperature. Cold storage is by in vitro testing superior to storage at ambient temperature, and data show that both platelet function in general and clot formation capability is preserved for at least ten days. We (Hervig lab) are presently conducting studies on platelet function and activation during storage, and we have found little platelet activation during storage for ten days. One goal is to store whole blood for clinical use in ten days, and after that period produce high quality red cell concentrates from the stored whole blood units.
Concerning the quality of reconstituted whole blood, there are many papers dealing with quality control, storage and transfusion of blood components. (38, 39) However, there has been little focus on the effects of the different storage times that are involved in reconstituted leucocyte reduced whole blood. "Transfusion packs" may be composed of red cell concentrates for 1-42 days, platelet concentrates stored for 1-7 days, and the plasma may be fresh frozen or thawed.
We have conducted a study (Hervig et al, Blood transfusion, in press) where we have investigated effects of red cell and platelet storage times on key platelet functions as aggregation response and thrombin formation after collagen stimulation. The experiments showed significant differences in responses depending on the age composition of the cellular components. It may seem that changes in the red cell membrane could be of importance, which also is indicated in published studies.
Predicting Risk of Massive Transfusions
With the demonstrated benefit of targeting high plasma and platelet transfusion ratios in those patients that ultimately require massive transfusion (MT) it is essential that massive transfusion can be predicted relatively early, soon after presentation to the trauma center in a large requirements. An ABC score of >= 2 was 75% sensitive and 86% specific for predicting MT, correctly classified 85%.
In addition to clinical scoring systems, there are objective laboratory measurements of predicting massive transfusion including the use of tissue oxygenation (StO2). In one large study, a multicenter trial of 383 severely injured patients, StO2 measured in the first hour after Emergency Department (ED) arrival predicted development of multiple organ dysfunction or death as well as or better than systolic blood pressure, serum lactate, and base deficit. (46) Additionally, data from this study showed that StO2 was the only parameter that could provide early (at one, two, and three hours after arrival) prediction of bad outcomes in patients requiring massive transfusion (10 units of PRBC in 24 hours). These results demonstrate that StO2 is a sensitive predictor of a poor outcome resulting from clinically significant hypo perfusion. (47) An example of the ability of StO2 to specifically signal the need for transfusion comes from a recent clinical study involving 26 trauma patients at risk for hemorrhagic shock. Results from this study showed that of patients who required a transfusion within 24 hours of arrival in the ED, 88% had a minimum StO2below 70% in the first hour of arrival in the ED, and of those who did not require a transfusion, only 22% had StO2 values that dropped below 70% for the first hour. (48)
Does Whole Blood Improve Outcomes?
There have been limited studies and mixed results on the use of whole blood in traumatic hemorrhagic shock concerning transfusions requirements and outcomes. Despite the use of > 800,000 units of Type O whole blood used by the US military during WWII and > 300,000 units low titer Type O whole blood used in Vietnam, there is little data on impact in its outcomes in hemorrhagic shock, either positive or negative. In one civilian study, a linked data cohort study still unclear due to protocol requirement of 1 unit of platelets (20°C) to be transfused with every 6 units of cold stored whole blood. This modification was necessary due to the funding agency's institutional review board requirement that every PRBC and whole blood unit be leukoreduced resulting in platelets being cleared by the filtration process. Additionally there were concerns about platelet non-functional status due to platelet aggregation at 1-6°C for up to 5 days.
As previously discussed in this paper, the most recent evidence by Pidcoke et al demonstrates platelet function is actually preserved for up to 10 days in cold storage of 4°C, thus unnecessary to give warm platelets (20°C) in addition to cold stored whole blood. It is also difficult to determine the total number of units of whole blood given to the modified whole blood group, which may have significant implications on total transfusion volumes, coagulation, and complications either for or against cold stored whole blood as an initial blood resuscitation product. Finally, the study was a pilot trial and not powered for mortality outcomes, which is often the gold standard when comparing resuscitation method outcomes.
One other prospective randomized trial comparing whole blood to component therapy has been 
Component vs. Whole Blood in Trauma Trial (COW BITT)
There is little and contradictory data regarding the potential benefits and risks of whole blood use in traumatic hemorrhagic shock patients. The use of whole blood instead of component therapy may result in faster resolution of shock and coagulopathy, decreased overall transfusion Patients with blunt or penetrating injured patients presenting with hemorrhagic bleeding meeting the inclusion/exclusion criteria (Table III) will be randomized.
Objective of the trial:
1. Evaluate whether LTLR Type O whole blood as compared to component blood transfusion will result in a lower incidence of mortality in patients at risk for massive transfusion from traumatic hemorrhagic bleeding.
2. Determine whether LTLR Type O whole blood (up to 10 units) as compared to standard component blood reduces the multiple system organ dysfunction (MSOD) rate, acute lung injury, nosocomial infection, shock parameters, early resuscitation and transfusion need, and thrombosis/embolic events. units of blood in 24 hours post injury). Again, using the Glue Grant dataset, for those patients who required between < 10 units of PRBC over the initial 24 hours following injury, the mortality rate was 8.3%. For our sample size estimation for the 30-day mortality outcome, we chose a difference of 14% (22% to 8%) from a baseline mortality of 22% when comparing patients randomized to LTLR Type O whole blood versus standard component therapy. The trial will be powered at 88% with a two-sided alpha level of 0.05 requiring a sample size of 150 patients per group.
Summary
In civilian medicine, blood component therapy has reduced the utilization of whole blood to a minimum in countries that can afford blood component production. Thus the focus on whole blood as a therapeutic blood component has been neglected except in austere environments or special situations. There are been little data to support the shift away from whole blood resuscitation in traumatic hemorrhagic shock and recent data from wars in Iraq and Afghanistan support that whole blood in early resuscitation may impact mortality and morbidity. Moreover, the hemostatic effects of cold-store whole blood are maintained longer than previously thought.
A multicenter prospective randomized trial comparing whole blood vs. component therapy is needed to evaluate whether whole blood can truly improve outcomes with adverse effects. 
